Trial Profile
An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 24 Mar 2009 Actual end date changed from Dec 2002 to Jun 2005 as reported by ClinicalTrials.gov record (NCT00048139).
- 20 May 2008 New trial record.